###### Strengths and limitations of this study

-   This study included a large number of participants, accounting for gender and smoking status.

-   A median follow-up period was 5 years.

-   This study findings are limited to workers in Japan.

-   We investigated whether haemoglobin A1c was associated with hearing impairment among participants with diabetes at baseline.

-   Information on noise exposure, ototoxic drug use, ear surgery and ear infection was not obtained.

Background {#s1}
==========

Patients with hearing impairment experience a range of complications, including impaired quality of life, dementia, depression, loneliness, poor self-esteem and functional disability.[@R1] These complications have made this condition a social and economic problem worldwide. More than 5% of the world population has hearing impairment, and this is expected to increase with the ageing of the population.[@R5] Although this bleak picture points to the importance of identifying preventable risk factors for hearing impairment, such studies are in fact scarce.

Emerging evidence suggests that diabetes mellitus may be a risk factor for hearing impairment. Meta-analyses of 13 cross-sectional studies showed that subjects with diabetes had a twofold increased risk of developing hearing impairment (OR 2.15, 95% CI 1.72 to 2.68).[@R6] Diabetic hearing impairment is hypothesised to be due to microvascular complications.[@R7] Diabetic hearing impairment may thus be prevented by appropriate glycaemic control, which has been shown to be effective for other microvascular complications of diabetes, such as retinopathy, nephropathy and neuropathy.[@R9] Three studies have reported the association between hearing impairment and haemoglobin A1c (HbA1c), an indicator for glycaemic control.[@R13] One of these reported a positive dose--response relationship between HbA1c and hearing impairment as defined using a pure-tone average threshold of mainly low frequencies,[@R15] while the other two reported that HbA1c was positively associated with high-frequency hearing impairment.[@R13] Nevertheless, no study has yet reported the precise shape of the dose--response relationship between HbA1c and high-frequency hearing impairment. Furthermore, no study has yet investigated whether HbA1c is associated with hearing impairment among those with diabetes.

In Japan, a pure-tone audiometric test is mandatory in annual occupational health check-ups.[@R16] The large sample size this affords has enabled us to investigate the dose--response relationship between HbA1c and hearing impairment, while accounting for well-known risk factors of hearing impairment such as gender and smoking.[@R17] The present study had two aims. The first aim was to investigate the association between HbA1c and the incidence of hearing impairment using a large dataset from annual occupational health check-ups in Japan, accounting for gender and smoking status. The second aim was to determine whether HbA1c was associated with hearing impairment among participants with diabetes.

Methods {#s2}
=======

Study population {#s2a}
----------------

The present study was conducted using data from annual health check-ups of Japanese workers. The All Japan Labor Welfare Foundation, a health service provider with centres in Tokyo, Aomori, Nagano, Yamagata, Ibaraki, Gunma and Nagoya provided the data from April 2008 to December 2015, allowing a maximum of 7 years of follow-up. In Japan, annual health check-ups are mandatory for all employees and include a hearing test under the Industrial Safety and Health Act. Nearly all employees attend a health check-up every year. Participants were mainly Japanese employees but also included a small number of their dependents, employers and foreign workers.

A total of 312 512 participants aged 30--65 years underwent a hearing test and HbA1c test at baseline (between April 2008 and March 2009). Of these, we excluded participants with hearing impairment at baseline (n=51 489). Given that patients with diabetes with complications may receive more intensive treatments, which may bias the association between HbA1c and hearing impairment, we excluded participants with cardiovascular disease and stroke (n=913). We further excluded participants who did not attend any subsequent health examinations or hearing tests (n=48 618). After further exclusion of 8517 participants with missing information on covariates (5011 for smoking status, 5152 for alcohol consumption, 1815 for physical activity data, 5 for body mass index (BMI), 9 for hypertension and 9 for dyslipidaemia data; some participants had missing data for more than one parameter), leaving 202 975 participants (131 689 men and 71 286 women) for analysis.

Before March 2013, we disclosed the purpose of our study by posters and the participants had the opportunity to refuse the use of their data for the study. This procedure conforms to the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects, where the obtaining consent may be simplified for observational studies using existing data.

Ascertainment of hearing impairment {#s2b}
-----------------------------------

Trained staff performed pure-tone air-conduction audiometry using an audiometer (AA-57, RION, Tokyo, Japan). Low-frequency hearing impairment was defined as failure to hear a pure-tone signal of 30 dB at 1 kHz in the better ear, and high-frequency hearing impairment as failure to hear a pure-tone signal of 40 dB at 4 kHz in the better ear. These thresholds are recommended for use in annual health check-ups by Ministry of Health, Labour and Welfare in Japan.[@R16] Onset of hearing impairment was defined as the day of the health check-up on which hearing impairment was first detected.

Data collection and measurements at baseline (between April 2008 and March 2009) {#s2c}
--------------------------------------------------------------------------------

We used a self-administered questionnaire developed by the Ministry of Health, Labour and Welfare for a specific health examination, namely the national health check-up system focused on metabolic syndrome,[@R19] to assess medical history, regular physical activity (walking time \<60 min/day or ≥60 min/day), smoking status (non-smoker, daily smoker ≤20 cigarettes/day or \>20 cigarettes/day), alcohol consumption (non-drinker,\<1 go, 1 to \<2 go or ≥2 go/day; 1 go of sake, a traditional Japanese beverage, is equal to about 180 mL of 10%--14% ethanol and contains about 23 g of ethanol),[@R20] and self-reported diabetes (treatments with antidiabetic medication or a self-reported history of diabetes: yes or no). Job type was categorised as professional job, management, office job, sales, service, telegraph, manufacturing, transportation and other. Height was measured to the nearest 0.1 cm and weight to the nearest 0.1 kg. BMI was calculated as the weight in kilograms divided by the square of height in metres and categorised into four groups (\<18.5, 18.5--22.9, 23--29.9 and ≥30 kg/m²). Blood pressure was measured in the sitting position using an automated sphygmomanometer (HEM-907, Omron, Kyoto, Japan). Participants with high blood pressure (≥130 mm Hg systolic or ≥85 mm Hg diastolic) received a second measurement and the average was used for the analysis. Hypertension was defined by ≥140 mm Hg systolic, ≥90 mm Hg diastolic or the use of medication for hypertension. A venous blood sample was collected and stored in a cooler at 4°C for transportation to an external laboratory (SRL, Tokyo, Japan). Triglyceride level was measured using an enzymatic colorimetric test and high-density lipoprotein cholesterol (HDL-C) was determined using a direct method. Dyslipidaemia was defined by triglyceride ≥150 mg/dL (1.7 mmol/L) in men and women, HDL-C \<40 mg/dL (1.04 mmol/L) in men and \<50 mg/dL (1.3 mmol/L) in women or use of medication for dyslipidaemia. HbA1c was measured by latex agglutination turbidimetry and converted to the National Glycohemoglobin Standardization Program equivalent value (%) using the formula below, according to the Japan Diabetes Society statement[@R21]:

HbA1c (%)=1.02×HbA1c (Japan Diabetes Society) (%)+0.25%

Diabetes was defined as FPG≥126 mg/dL, HbA1c≥6.5% or self-reported diabetes.

Statistical analysis {#s2d}
--------------------

Participants were divided into seven groups according to their HbA1c level at baseline (\<5.0% (91mg/dL), 5.0%--5.4% (91-110mg/dL), 5.5%--5.9% (111-125mg/dL), 6.0%--6.4% (126-139mg/dL), 6.5%--6.9% (140-153mg/dL), 7.0%--7.9% (154-182mg/dL), ≥8.0% (183mg/dL)). The HbA1c group specific baseline characteristics of participants were described as means (SD) for continuous variables and percentages for categorical variables. Person-year was calculated from baseline to the onset of hearing impairment, or the date of the last health check-up to December 2015 (whichever occurred first). Crude incident rates of hearing impairment were shown in events per 1000 person-years. Survival analyses were performed using Cox regression to estimate the HR with 95% CI for the incidence of hearing impairment across HbA1c categories, with 5.0%--5.4% (31--36 mmol/mol) as the reference value. The analyses were stratified by sex because the interaction between hearing impairments and sex was significant (p for interaction \<0.001). Age-adjusted model (model 1) and multiple-adjusted model (model 2), which included alcohol consumption, physical activity, BMI, hypertension, dyslipidaemia, self-reported diabetes and smoking status were used for the analysis. Although smoking status itself was related to hearing impairment in this study, the association between HbA1c and hearing impairment differed according to smoking status (p for interaction \<0.001). We, therefore, additionally performed analyses according to combined HbA1c (seven groups) and smoking status (non-smoker and current smoker), by considering HbA1c 5.0%--5.4% (31--36 mmol/mol) and non-smoker as the reference category. We did not analyse women's smokers because of the small number of cases. To assess whether control of HbA1c would reduce the incidence of hearing impairment in those with diabetes, we elucidated the shape of the relationship between HbA1c and high-frequency hearing impairment among those with diabetes. We fitted restricted cubic splines models with seven knots placed at the 1th, 5th, 25th, 50th, 75th, 95th and 99th centiles as reference values of HbA1c 6.6% (25th).[@R22] The HRs were adjusted for alcohol consumption, physical activity, BMI, hypertension, dyslipidaemia and smoking status. As a sensitivity analysis, we further adjusted for job type in the main analyses (model 2) among participants with this information (n=126 823). We tested the proportional hazards assumption using Schoenfeld residuals. We found no significant deviations for any covariate. P value of two-tailed test \<0.05 was considered statistically significant. Trend association was assessed by assigning ordinal numbers (0--6) to the HbA1c categories. We calculated the p for the quadratic trend because it was a better ﬁt for the data than the simple linear model. All statistical analyses were performed using Stata V.12.1 (StataCorp).

Patient and public involvement {#s2e}
------------------------------

No patient and public were involved in setting the research question or the outcome measures, planning for the design of the study.

Results {#s3}
=======

Baseline characteristics by category of HbA1c are shown in [table 1](#T1){ref-type="table"}. The mean age of participants was 45 years for men and 47 years for women. Participants who had higher HbA1c tended to be non-drinkers and to have higher BMI, hypertension and dyslipidaemia in both men and women. Male participants with higher HbA1c tended to be smokers consuming \>20 cigarettes per day.

###### 

Baseline characteristics of study participants according to HbA1c (n=202 975)

                                          HbA1c (%) (mg/dL)                                                                                 
  --------------------------------------- ------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------
  Men                                                                                                                                       
   n                                      131 689             10 701       53 839       50 957       8995         2488         2224         2485
   Age (years)\*                          44.6 (9.1)          40.9 (8.2)   42.6 (8.6)   45.7 (9.0)   49.6 (8.6)   51.7 (7.9)   51.6 (7.8)   49.2 (8.2)
   Walking time, ≥60 min/day (%)          16                  16           17           17           15           15           16           13
   Smoking status (%)                                                                                                                       
    Non-smoker                            45.15               44           44           46           47           50           46           40
    Daily consuming ≤20 cigarettes/day    37.04               39           39           36           34           31           32           35
    Daily consuming \>20 cigarettes/day   17.8                17           17           18           19           19           22           25
    Alcohol consumption (%)                                                                                                                 
    Non-drinker                           26                  19           24           29           31           30           33           36
    Drinker \<1 go/day†                   35                  32           35           36           34           34           30           32
    Drinker 1 to \<2 go/day†              26                  30           27           25           25           25           26           22
    Drinker ≥2 go/day†                    12                  19           13           10           10           11           11           10
   Self-reported diabetes (%)‡            2.3                 0.07         0.10         0.4          4.6          22.4         41.1         37.3
   BMI (kg/m^2^)\*                        23.8 (3.5)          22.6 (2.9)   23.2 (3.1)   24.0 (3.5)   25.4 (4.0)   26.0 (4.2)   26.3 (4.3)   26.4 (4.5)
   Hypertension (%)§                      28                  21           22           29           44           57           57           53
   Dyslipidaemia (%)¶                     39                  29           33           41           54           59           60           65
  Women                                                                                                                                     
   n                                      71 286              5880         28 277       29 741       5286         890          618          594
   Age (years)\*                          47.1 (9.0)          41.5 (7.6)   44.6 (8.6)   49.0 (8.6)   52.6 (7.6)   53.9 (7.2)   53.9 (7.2)   52.0 (7.6)
   Walking time, ≥60 min/day (%)          12                  11           11           12           13           12           13           11
   Smoking status (%)                                                                                                                       
    Non-smoker                            80                  71           77           83           86           86           83           77
    Daily consuming ≤20 cigarettes/day    19                  26           21           16           13           13           16           22
    Daily consuming \>20 cigarettes/day   1.4                 2.5          1.5          1.2          1.2          1.1          1.5          1.9
   Alcohol consumption (%)                                                                                                                  
    Non-drinker                           60                  45           56           65           70           74           73           78
    Drinker \<1 go/day†                   31                  36           34           29           26           22           22           19
    Drinker 1 to \<2 go/day†              6.8                 14.4         7.8          5.0          3.8          3.9          3.7          2.7
    Drinker ≥2 go/day†                    1.7                 5.3          1.9          1.0          0.5          0.6          0.5          0.7
   Self-reported diabetes (%)‡            1.2                 0.05         0.03         0.1          2.5          17.4         38.2         47.5
   BMI (kg/m^2^)\*                        22.3 (3.6)          21.2 (2.9)   21.6 (3.2)   22.5 (3.7)   23.9 (4.3)   25.5 (4.7)   26.4 (4.8)   26.6 (4.6)
   Hypertension (%)§                      19                  11           14           21           34           52           59           53
   Dyslipidaemia (%)¶                     22                  13           16           24           39           54           61           59

Longitudinal survey of 202 950 examinees in All Japan Labor Welfare Foundation, Japan, 2008.

\*Mean (SD).

†1 go contains \~23 g of ethanol.

‡Self-reported diagnosis of diabetes or receiving medication.

§Systolic blood pressure≥140 mm Hg, diastolic blood pressure≥90 mm Hg or receiving medication.

¶Triglyceride level ≥150 mg/dL (1.7 mmol /L), high-density lipoprotein cholesterol level \<40 mg/dL (1.04 mmol /L) in men and \<50mg/dL (1.3 mml/L) in women or receiving medication.

HbA1c, haemoglobin A1c.

In men, 4621 developed high-frequency hearing impairment with 661 937 person-years (mean duration of follow-up was 5.0 years) and 1311 developed low-frequency hearing impairment with 670 153 person-years (5.1 years). In women, 582 developed high-frequency hearing impairment with 345 312 person-years (4.8 years) and 1207 developed low-frequency hearing impairment with 344 057 person-years (4.8 years). [Table 2](#T2){ref-type="table"} shows the association between HbA1c and the incidence of hearing impairment. In the multivariable-adjusted model, HbA1c showed a quadratic trend with the incidence of high-frequency hearing impairment in men (p for quadratic=0.007), and a statistically marginal association in women (p for quadratic=0.08). HbA1c was not associated with low-frequency hearing impairment. [Figure 1](#F1){ref-type="fig"} shows the association between HbA1c and high-frequency hearing impairment with accounting for smoking status (the interaction between HbA1c and smoking status (p for interaction \<0.001)). Compared with non-smokers with HbA1c 5.0%--5.4% (31--36 mmol/mol), non-smokers with HbA1c≥8.0% (64 mmol/mol) showed an association with hearing impairment (HR (95% CI) of 1.46 (1.11 to 1.92) in men and 2.36 (1.34 to 4.15) in women). Although smokers had higher HRs of hearing impairment than non-smokers, HbA1c level was not associated with hearing impairment among smokers. Additional adjustments for job type did not affect the results (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}).
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![The association between haemoglobin A1c (HbA1c) and hearing impairment of high frequency stratified by smoking status. Results obtained by multivariable Cox regression. The reference value was 5.0%--5.4% of HbA1c in non-smoker. The model was adjusted for age (year, continuous), sex, body mass index (\<18.5, 18.5--22.9, 23--29.9 or ≥30.0 kg/m^2^), alcohol consumption (non-drinker, drinker consuming \<1, 1 to \<2 or ≥2 go of Japanese sake contains approximately 23 g of ethanol), walking time (\<60 or ≥60 min/day), self-reported diabetes, hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg or receiving medication) and hyperlipidaemia (triglyceride level ≥150 mg/dL, high-density lipoprotein cholesterol level \<40 mg/dL or receiving medication).](bmjopen-2018-023220f01){#F1}

###### 

HR of hearing impairment according to baseline HbA1c (n=202 975)

                   HbA1c (%) (mg/dL)     P for quadratic                                                                                                                 
  ---------------- --------------------- ----------------- --------------------- --------------------- --------------------- --------------------- --------------------- -------
  Low frequency                                                                                                                                                          
   Men                                                                                                                                                                   
    Person-year    54 055                275 953           261 290               44 807                11 798                10 637                11 613                
    No cases       84                    447               548                   122                   45                    26                    39                    
    Model 1        1.15 (0.91 to 1.45)   1.00              0.98 (0.86 to 1.11)   0.94 (0.77 to 1.15)   1.11 (0.81 to 1.51)   0.73 (0.49 to 1.08)   1.22 (0.88 to 1.70)   0.15
    Model 2        1.11 (0.88 to 1.40)   1.00              1.00 (0.88 to 1.14)   0.98 (0.79 to 1.20)   1.16 (0.84 to 1.60)   0.75 (0.49 to 1.15)   1.26 (0.88 to 1.80)   0.27
   Women                                                                                                                                                                 
    Person-year    28 447                137 761           143 295               25 083                4136                  2760                  2576                  
    No cases       65                    415               553                   133                   18                    14                    9                     
    Model 1        1.04 (0.80 to 1.35)   1.00              0.90 (0.79 to 1.03)   0.94 (0.77 to 1.14)   0.71 (0.44 to 1.14)   0.86 (0.51 to 1.48)   0.68 (0.35 to 1.31)   0.79
    Model 2        1.04 (0.80 to 1.35)   1.00              0.91 (0.80 to 1.03)   0.93 (0.76 to 1.14)   0.67 (0.41 to 1.10)   0.77 (0.43 to 1.38)   0.57 (0.28 to 1.19)   0.51
  High frequency                                                                                                                                                         
   Men                                                                                                                                                                   
    Person-year    53 617                273 025           257 812               44 093                11 621                10 345                11 424                
    No cases       280                   1610              1941                  416                   116                   128                   130                   
    Model 1        1.05 (0.92 to 1.19)   1.00              0.98 (0.91 to 1.04)   0.91 (0.82 to 1.02)   0.82 (0.67 to 0.99)   1.05 (0.88 to 1.26)   1.15 (0.96 to 1.38)   0.003
    Model 2        1.03 (0.90 to 1.17)   1.00              0.99 (0.92 to 1.06)   0.93 (0.83 to 1.03)   0.84 (0.69 to 1.02)   1.08 (0.89 to 1.32)   1.18 (0.97 to 1.43)   0.007
   Women                                                                                                                                                                 
    Person-year    28 520                138 232           143 882               25 246                4124                  2753                  2555                  
    No cases       23                    169               277                   67                    18                    13                    15                    
    Model 1        1.02 (0.66 to 1.58)   1.00              1.00 (0.83 to 1.22)   0.97 (0.73 to 1.29)   1.43 (0.88 to 2.34)   1.62 (0.92 to 2.86)   2.41 (1.42 to 4.10)   0.03
    Model 2        1.03 (0.66 to 1.60)   1.00              0.97 (0.80 to 1.17)   0.86 (0.64 to 1.16)   1.17 (0.70 to 1.95)   1.24 (0.67 to 2.29)   1.78 (0.95 to 3.34)   0.08

Model 1: Adjusted for age.

Model 2: Adjusted for age, walking time, smoking status, alcohol consumption, self-reported diabetes, BMI, hypertension and hyperlipidaemia.

BMI, body mass index; HbA1c, haemoglobin A1c.

[Figure 2](#F2){ref-type="fig"} shows the spline regression model of high-frequency hearing impairment at various HbA1c levels against a reference HbA1c level of 6.6% in participants with diabetes at baseline (n=10 154). The relationship between HbA1c and the incidence of hearing impairment was J-shaped, with the significant increase of HR for HbA1c≥7.2%.

![Adjusted HR of high-frequency hearing impairment among participants with diabetes at baseline (n=10 154). Results obtained by multivariable Cox regression with restricted cubic splines with seven knots (p1, p5, p25, p50, p75, p95 and p99). The reference value was 6.6% (p25) of HbA1c. The continuous line presents HRs and the dashed line presents 95% CIs. The model was adjusted for age (year, continuous), sex, body mass index (\<18.5, 18.5--22.9, 23--29.9 or ≥30.0 kg/m^2^), smoking status (non-smoker, smoker consuming ≤20 or \>20 cigarettes per day), alcohol consumption (non-drinker, drinker consuming\<1, 1 to\<2 or ≥2 go of Japanese sake contains approximately 23 g of ethanol), walking time (\<60 or ≥60 min/day), hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg or receiving medication) and hyperlipidaemia (triglyceride level≥150 mg/dL, high-density lipoprotein cholesterol level\<40 mg/dL in men and \<50 mg/dL in women or receiving medication). HbA1c, haemoglobin A1c.](bmjopen-2018-023220f02){#F2}

Discussion {#s4}
==========

In this study, we found a quadratic trend between HbA1c and the incidence of high-frequency hearing impairment. In particular, HbA1c concentrations over 8.0% (64 mmol/mol) were associated with high-frequency hearing impairment among non-smokers. A J-shaped association between HbA1c and high-frequency hearing impairment was observed among participants with diabetes at baseline. Our findings indicate that appropriate glycaemic control may prevent the incidence of diabetic hearing impairment.

Our finding of a quadratic trend between HbA1c and hearing impairment is supported by the results of two longitudinal studies.[@R13] One of these reported an OR (95% CI) of high-frequency hearing impairment per 1.0% increase in HbA1c of 1.52 (1.03 to 2.23), although no statistical association between the three categories of HbA1c and high-frequency hearing impairment.[@R13] The second reported that HbA1c was positively associated with average hearing threshold, mainly among low frequencies.[@R15] The present study provides novel evidence that an HbA1c of 8.0% (64 mmol/mol) or above is associated with increased risk of high-frequency hearing impairment in non-smokers. Our findings are consistent with the work of Cruickshanks *et al*, who reported that poor glycaemic control, defined by a glycosylated haemoglobin level, was associated with hearing impairment.[@R23]

Additionally, we found that the J-shaped association between HbA1c and hearing impairment remained even among participants with diabetes at baseline. This result suggests that proper glycaemic control may prevent diabetic-related hearing impairment even in those with diabetes. Previous studies have also reported a J-shaped association between HbA1c and diabetics complications, and noted that hypoglycaemia might increase diabetic complications.[@R24] More research is needed to determine a suitable HbA1c level for glycaemic targeting to prevent hearing impairment in diabetic management.

We found that high-frequency hearing impairment has a quadratic trend with HbA1c among non-smokers but not smokers. Previous studies have reported an adverse effect of smoking cigarettes on hearing impairment.[@R23] It is plausible that the effect of smoking cigarettes may be stronger than HbA1c and might mask the effect of HbA1c. Further research is needed to confirm the joint effect of smoking and HbA1c on hearing impairment.

The pathophysiology underlying high-HbA1c-associated hearing impairment is unclear, which allows for speculation. One possible explanation is that hyperglycaemia-related microvascular complications lead to thickening of the cochlea and vestibulopathy, and result in hearing impairment.[@R7] Diabetic-related hearing impairment has been mainly observed at high frequencies, suggesting that high frequency-specific areas of the cochlea may be more fragile to ischaemic changes due to microvascular complications.[@R34] This mechanism is supported by the J-shaped association between HbA1c and hearing impairment observed in the present study, since previous studies also reported a J-shaped-association between HbA1c and diabetic vascular complications.[@R39] Further studies to confirm this idea are required.

This study has several strengths. The large dataset allowed us to investigate the association between HbA1c and hearing impairment with comprehensive adjustment for covariates, and additionally, among participants with diabetes at baseline. Audiometry to confirm hearing impairment was conducted by trained staff. Several limitations of the study also need to be considered. First, though noise exposure is an important risk factor on hearing impairment,[@R41] information on noise exposure was not available, and thus, noise information was not considered in the analyses. The present study thus might include the cofounding influence of noise exposure. However, a previous study reported that the relationship between diabetes and hearing impairment was independent of this variable.[@R37] Moreover, in the present study, HbA1c level was associated with hearing impairment even after accounting for job type in a sensitivity analysis. Second, information on ototoxic drug use, ear surgery and ear infection was not collected, and we were therefore unable to exclude cases of hearing impairment due to these factors. Third, blood pressure was measured once, followed by a second measurement if the first systolic blood pressure ≥130 mm Hg systolic or diastolic blood pressure ≥85 mm Hg. All participants did not have the same evaluation of blood pressure. This may lead to misclassification of hypertension. Fourth, we did not account for gender or smoking status in the association between HbA1c and hearing impairment for participants with diabetes because of the small sample size. Fifth, the hearing test was only conducted at 1 kHz and 4 kHz. Hearing impairment at other frequencies could not therefore be identified. Sixth, we cannot exclude the possibility of residual confounding and confounding by unmeasured variables. Finally, the study participants were mainly workers, and thus, caution is required when generalising our findings.

Conclusion {#s5}
==========

We found the quadratic trend between HbA1c and the incidence of high-frequency hearing impairment in non-smokers. The trend between HbA1c and hearing impairment remained even among those with diabetes. These findings indicate that diabetic-related hearing impairment may be prevented with appropriate glycaemic control. These findings warrant confirmation in interventional studies.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

The authors would like to thank Nobuo Yanagisawa and Takeshi Kawaguchi for coordinating the study.

**Contributors:** SN, TaM and IK designed study and drafted the manuscript. SN, HH, KaK, AN and KeK performed the data analysis. MD collected and interpreted the data. All authors participated in interpretation of the findings, revised the paper critically for important intellectual content and approved the final version to be published. YN and YM provided administrative, technical and material support. TeM and SA revised the work critically for important intellectual content. SN and YN are guarantors.

**Funding:** This research was funded by All Japan Labor Welfare Foundation Research Fellowship.

**Disclaimer:** All Japan Labor Welfare Foundation had no role in the design, analysis or writing of this articles.

**Competing interests:** SN is occupational physicians in All Japan Labor Welfare Foundation.

**Patient consent:** Obtained.

**Ethics approval:** The research protocol including consent procedure was approved by the Ethics Committee of the Faculty of Medicine, Toho University (No. 25 017 and No.A16130) and the Ethics Committee of the National Center for Global Health and Medicine (No. NCGM-G-0 01 254--02).

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** No additional data are available.
